{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:21:28Z","timestamp":1791321688086,"version":"4.3.1"},"reference-count":19,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:p>\n                    Antibiotic-resistant Enterobacteriaceae and\n                    <jats:italic toggle=\"yes\">Acinetobacter baumannii<\/jats:italic>\n                    are problematic pathogens, with few treatment options for multidrug-resistant (MDR)-\n                    <jats:italic toggle=\"yes\">A. baumannii<\/jats:italic>\n                    and few oral options for extended spectrum \u03b2-lactamase (ESBL)-producing and MDR-Enterobacteriaceae. Omadacycline, a newer tetracycline derivative, has activity against some of these pathogens. We tested the\n                    <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                    activity of omadacycline against a contemporary collection of over 2,600 consecutive unique clinical isolates of Enterobacteriaceae and\n                    <jats:italic toggle=\"yes\">A. baumannii<\/jats:italic>\n                    , a previous collection of carbapenem-resistant\n                    <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">A. baumannii<\/jats:italic>\n                    from a surveillance study in 2013\u20132014, and a group of\n                    <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">A. baumannii<\/jats:italic>\n                    isolates with previously defined resistance mechanisms. For the contemporary collection, over 96% of\n                    <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>\n                    and 70% of\n                    <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n                    isolates were inhibited by omadacycline at \u22644\u2009\u03bcg\/mL including 95% of\n                    <jats:italic toggle=\"yes\">E. coli<\/jats:italic>\n                    and 49% of\n                    <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n                    with presumptive ESBLs. Nearly 90% of\n                    <jats:italic toggle=\"yes\">A. baumannii<\/jats:italic>\n                    were inhibited by omadacycline at \u22644\u2009\u03bcg\/mL. The omadacycline MIC\n                    <jats:sub>50\/90<\/jats:sub>\n                    was 1\/4\u2009\u03bcg\/mL, 4\/&gt;8\u2009\u03bcg\/mL, and 0.5\/8 for\n                    <jats:italic toggle=\"yes\">E. coli<\/jats:italic>\n                    ,\n                    <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n                    , and\n                    <jats:italic toggle=\"yes\">A. baumannii<\/jats:italic>\n                    , respectively. For the carbapenem-resistant collection of isolates, 56% of\n                    <jats:italic toggle=\"yes\">A. baumannii<\/jats:italic>\n                    were inhibited by omadacycline at \u22644\u2009\u03bcg\/mL, but only 30% of\n                    <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>\n                    carbapenemase (KPC)-possessing\n                    <jats:italic toggle=\"yes\">K. pneumoniae<\/jats:italic>\n                    were susceptible. Expression of the efflux gene\n                    <jats:italic toggle=\"yes\">ade<\/jats:italic>\n                    B appeared to affect the activity of omadacycline against\n                    <jats:italic toggle=\"yes\">A. baumannii<\/jats:italic>\n                    , but could not fully explain resistance to this agent. Omadacycline may prove to be a parenteral or oral option for some infections due to ESBL-producing Enterobacteriaceae and carbapenem-resistant\n                    <jats:italic toggle=\"yes\">A. baumannii<\/jats:italic>\n                    , and clinical studies are warranted.\n                  <\/jats:p>","DOI":"10.1089\/mdr.2019.0423","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T21:42:18Z","timestamp":1593034938000},"page":"190-195","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":20,"title":["Activity of Omadacycline and Other Tetracyclines Against Contemporary Gram-Negative Pathogens from New York City Hospitals"],"prefix":"10.1177","volume":"27","author":[{"given":"Alejandro","family":"Iregui","sequence":"first","affiliation":[{"name":"Department of Medicine, SUNY Downstate Medical Center, Brooklyn, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Landman","sequence":"additional","affiliation":[{"name":"Department of Medicine, SUNY Downstate Medical Center, Brooklyn, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Quale","sequence":"additional","affiliation":[{"name":"Department of Medicine, SUNY Downstate Medical Center, Brooklyn, New York, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,6,22]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30753-3"},{"issue":"1","key":"e_1_3_3_3_2","first-page":"S24","article-title":"Antimicrobial susceptibility of Acinetobacter calcoaceticus-Acinetobacter baumannii complex and Stenotrophomonas maltophilia clinical isolates: results from the SENTRY antimicrobial surveillance program (1997\u20132016)","author":"Gales A.C.","year":"2019","unstructured":"Gales A.C., , Deifert H., , Gur D., , Castanheira M., , Jones R.N, , and Sader H.S.. 2019. Antimicrobial susceptibility of Acinetobacter calcoaceticus-Acinetobacter baumannii complex and Stenotrophomonas maltophilia clinical isolates: results from the SENTRY antimicrobial surveillance program (1997\u20132016). Open Forum Infect. Dis. 6, (Suppl 1)::S24\u2013S46.","journal-title":"Open Forum Infect. Dis. 6"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003126"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-019-03590-3"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2016.07.029"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1900188"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02327-17"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00830-15"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2015.02.018"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.012575-0"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01684-07"},{"key":"e_1_3_3_13_2","unstructured":"CLSI. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard\u2014Tenth edition. M07\u2013A10. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_3_14_2","unstructured":"Food U.S and Administration. Drug. 2019. Antibacterial susceptibility test interpretive criteria. 2019. Available at https:\/\/www.fda.gov\/drugs\/development-resources\/antibacterial-susceptibility-test-interpretive-criteria."},{"key":"e_1_3_3_15_2","unstructured":"EUCAST. 2019. Clinical breakpoints for bacteria. Available at http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_9.0_Breakpoint_Tables.pdf."},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04809-14"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2019.02.017"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01110-18"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.11.011"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02036-13"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2019.0423","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2019.0423","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2019.0423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:37:00Z","timestamp":1777667820000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/mdr.2019.0423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,22]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2,1]]}},"alternative-id":["10.1089\/mdr.2019.0423"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2019.0423","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,22]]}}}